Cargando…
Reporting of Allergic Reactions During Pfizer-BioNTech BNTT162B2 Vaccination in Israel
BACKGROUND: In December 2020, the Israeli Ministry of Health launched a national vaccination campaign against SARS-CoV-2. Concomitant sporadic reports on anaphylactic responses in other countries raised safety concerns at the outset of this operation. OBJECTIVE: To characterize reports on allergic r...
Autores principales: | Anis, Emilia, Preis, Sharon Alroy, Cedar, Noa, Tal, Yuval, Hershkowitz, Isca, Hershko, Alon Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356746/ https://www.ncbi.nlm.nih.gov/pubmed/35872216 http://dx.doi.org/10.1016/j.jaip.2022.07.012 |
Ejemplares similares
-
Administration of BNT162b2 mRNA COVID-19 vaccine to subjects with various allergic backgrounds
por: Ribak, Yaarit, et al.
Publicado: (2023) -
Myocarditis with Pfizer-BioNTech's COVID-19 vaccine in Israel
Publicado: (2021) -
Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
por: Lustig, Yaniv, et al.
Publicado: (2021) -
Managing allergic reactions to Pfizer-BioNTech COVID-19 vaccine
Publicado: (2021) -
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study
por: Haas, Eric J, et al.
Publicado: (2022)